-
1
-
-
70350066163
-
Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control
-
Aronov, A.M., Tang, Q., Martinez-Botella, G. et al. (2009). Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J. Med. Chem. 52, 6362-6368.
-
(2009)
J. Med. Chem.
, vol.52
, pp. 6362-6368
-
-
Aronov, A.M.1
Tang, Q.2
Martinez-Botella, G.3
-
2
-
-
84875235432
-
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
-
Ascierto, P.A., Schadendorf, D., Berking, C. et al. (2013). MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 14, 249-256.
-
(2013)
Lancet Oncol.
, vol.14
, pp. 249-256
-
-
Ascierto, P.A.1
Schadendorf, D.2
Berking, C.3
-
3
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman, P.B., Hauschild, A., Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
-
4
-
-
84868224906
-
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
-
Flaherty, K.T., Infante, J.R., Daud, A. et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703.
-
(2012)
N. Engl. J. Med.
, vol.367
, pp. 1694-1703
-
-
Flaherty, K.T.1
Infante, J.R.2
Daud, A.3
-
5
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
-
Hauschild, A., Grob, J.J., Demidov, L.V. et al. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365.
-
(2012)
Lancet
, vol.380
, pp. 358-365
-
-
Hauschild, A.1
Grob, J.J.2
Demidov, L.V.3
-
6
-
-
84880064248
-
Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity
-
Ishii, N., Harada, N., Joseph, E.W. et al. (2013). Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res. 73, 4050-4060.
-
(2013)
Cancer Res.
, vol.73
, pp. 4050-4060
-
-
Ishii, N.1
Harada, N.2
Joseph, E.W.3
-
7
-
-
84870289371
-
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
-
Kwong, L.N., Costello, J.C., Liu, H. et al. (2012). Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat. Med., 18, 1503-1510.
-
(2012)
Nat. Med.
, vol.18
, pp. 1503-1510
-
-
Kwong, L.N.1
Costello, J.C.2
Liu, H.3
-
8
-
-
84869067183
-
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas
-
Lito, P., Pratilas, C.A., Joseph, E.W. et al. (2012). Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22, 668-682.
-
(2012)
Cancer Cell
, vol.22
, pp. 668-682
-
-
Lito, P.1
Pratilas, C.A.2
Joseph, E.W.3
-
9
-
-
84900442808
-
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors
-
Lito, P., Saborowski, A., Yue, J. et al. (2014). Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell, 25, 697-710.
-
(2014)
Cancer Cell
, vol.25
, pp. 697-710
-
-
Lito, P.1
Saborowski, A.2
Yue, J.3
-
10
-
-
84896757312
-
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma
-
Ma, X.H., Piao, S.F., Dey, S. et al. (2014). Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J. Clin. Investig. 124, 1406-1417.
-
(2014)
J. Clin. Investig.
, vol.124
, pp. 1406-1417
-
-
Ma, X.H.1
Piao, S.F.2
Dey, S.3
-
11
-
-
77953276524
-
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
-
Paraiso, K.H., Fedorenko, I.V., Cantini, L.P., Munko, A.C., Hall, M., Sondak, V.K., Messina, J.L., Flaherty, K.T., and Smalley, K.S. (2010). Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer 102, 1724-1730.
-
(2010)
Br. J. Cancer
, vol.102
, pp. 1724-1730
-
-
Paraiso, K.H.1
Fedorenko, I.V.2
Cantini, L.P.3
Munko, A.C.4
Hall, M.5
Sondak, V.K.6
Messina, J.L.7
Flaherty, K.T.8
Smalley, K.S.9
-
12
-
-
84874613332
-
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
-
Posch, C., Moslehi, H., Feeney, L. et al. (2013). Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc. Natl Acad. Sci. USA 110, 4015-4020.
-
(2013)
Proc. Natl Acad. Sci. USA
, vol.110
, pp. 4015-4020
-
-
Posch, C.1
Moslehi, H.2
Feeney, L.3
-
13
-
-
84904087853
-
Evaluating melanoma drug response and therapeutic escape with quantitative proteomics
-
Rebecca, V.W., Wood, E.R., Fedorenko, I.V. et al. (2014). Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Mol. Cell. Proteomics, 13, 1844-1854.
-
(2014)
Mol. Cell. Proteomics
, vol.13
, pp. 1844-1854
-
-
Rebecca, V.W.1
Wood, E.R.2
Fedorenko, I.V.3
-
14
-
-
84891898344
-
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
-
Shi, H., Hugo, W., Kong, X. et al. (2014). Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4, 80-93.
-
(2014)
Cancer Discov
, vol.4
, pp. 80-93
-
-
Shi, H.1
Hugo, W.2
Kong, X.3
|